InflaRx posted a net loss of €16.2 million for the six months ended June 30, 2026, narrowing from €22.7 million a year earlier.
R&D expenses fell to €8.9 million from €14.2 million, mainly on lower third-party external services and reduced share-based payment costs.
G&A expenses dropped to €5.7 million from €8.3 million, driven by lower personnel costs and reduced legal and consulting fees.
Cash, cash equivalents and marketable securities totaled €158.4 million at June 30, 2026, with management projecting runway through 2029.
Pipeline focus shifted to Phase 2 planning for izicopan in ANCA-associated vasculitis, with initial open-label renal proof-of-concept data targeted in 2027.
IFRX•
